AudioMedica.comAuthor: AudioMedica.com
26 May 2019

AudioMedica.com

Download, listen or watch all podcasts

Medical News Interviews

  • Listen

    Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”

    Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”

    MUNICH—A “salutary lesson” was reported by researchers investigating therapy for oropharyngeal cancer at the 2018 annual congress of the European Society for Medical Oncology (ESMO). It came from results of the De-ESCALaTE HPVstudy that found patients with low-risk head and …

    Hisham Mehanna discusses head and neck cancer de-escalation

  • Posted on 12 Nov 2018

    download
  • Listen

    Which New Combination for Metastatic Renal Cell Cancer?

    Which New Combination for Metastatic Renal Cell Cancer?

    MUNICH—A leading European oncologist acknowledged the impressive life-extending potential of new drug combinations for metastatic renal cell carcinoma discussed at the 2018 annual congress of the European Society for Medical Oncology (ESMO). Progress was reported with purely immunological approaches—using two …

    John Haanen Audio Journal of Oncology

  • Posted on 12 Nov 2018

    download
  • Listen

    Two Drug Combination Doubled Kidney Cancer Progression Free Survival

    Two Drug Combination Doubled Kidney Cancer Progression Free Survival

    MUNICH— A doubling of progression free survival (PFS) and objective response rate (ORR) was observed in patients who had their previously untreated advanced renal cell cancer (RCC) treated with a combination of the vascular endothelial growth factor (VEGF) inhibitor axitinib …

    Robert Motzer ESMO AJO

  • Posted on 07 Nov 2018

    download
  • Listen

    ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 

    ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 

    MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK gene rearrangements as they are in clinical studies—even though randomized trials “cherry …

    Mohammad Jahanzeb AJ0

  • Posted on 07 Nov 2018

    download
  • Listen

    First Line PARP Inhibition For Ovarian Cancer Assessed

    First Line PARP Inhibition For Ovarian Cancer Assessed

    MUNICH—The role of poly ADP ribose polymerase (PARP) inhibitors for treating newly diagnosed advanced ovarian cancer was under review at the 2018 annual congress of the European Society for Medical Oncology (ESMO) in the light of findings from the SOLO1 …

    Jonathan Ledermann AJO

  • Posted on 02 Nov 2018

    download

Follow Playlisto